Study Summary for EVADE
The World Health Organization declared Coronavirus 2019 (COVID-19) a pandemic on March 11, 2020. As of September 8, 2020, over 27 million confirmed cases and 890,000 deaths from COVID-19 have occurred worldwide (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). Efforts are underway globally to rapidly develop vaccines against SARS-CoV-2. Once vaccines are introduced, it will be critical to document real-world vaccine effectiveness to inform vaccine recommendations and pandemic response efforts. SARS-CoV-2 vaccines are expected to be distributed during early phases of introduction to front-line health care personnel (HCP). This early phase distribution of one or more vaccines provides an opportunity to evaluate the effectiveness of these vaccines in preventing symptomatic COVID-19 infection and to learn how these vaccines work in real life setting before the widespread distribution to the general public, but after favorable Phase III results are released.
For Participants:
Important things to know:
- Taking part in research is voluntary. You can choose not to be in this study, or stop at any time.
- If you decide not to be in this study, your choice will not affect your healthcare or any services you receive. There will be no penalty to you. You will not lose medical care or any legal rights.
_________________________________________________________________________________________
What is this study about?
The purpose of this research study is to evaluate the effectiveness of SARS-COV2 vaccines in preventing COVID-19 infection and to learn how these vaccines work in a real life setting before the widespread distribution to the general public.
What will happen during the study?
If you choose to participate in this trial, the researchers will ask you to respond to eligibility questions, complete a baseline enrollment form around the time of COVID testing, and complete a follow-up survey approximately 4-6 weeks after testing.
These surveys may be completed electronically or via telephone.
How much time will I spend on the study?
You will be a part of this study for approximately 4 to 6 weeks, with 3 different contact points from enrollment to completion.
We anticipate the time commitment to be about 1-2 hours in filling the surveys
Could taking part in the study help me?
Being in this study does not provide any direct benefit to participants. This study will allow researchers to gain knowledge of the effectiveness of the SARS-COV2 prior to its release to the general public.
For questions about the study, contact the research team:
Nasia Safdar, MD, PhD
608-213-4075
University of Wisconsin-Madison, Division of Infectious Disease
Medical Foundation Centennial Bldg. 1685 Highland Ave, Madison, WI 53705
For questions about research participants’ rights, or for complaints, contact:
UW Health Patient Relations – 608-263-8009